Recursion Pharmaceuticals vs Cardinal Health

Side-by-side comparison of AI visibility scores, market position, and capabilities

Cardinal Health leads in AI visibility (79 vs 56)
Recursion Pharmaceuticals logo

Recursion Pharmaceuticals

ChallengerHealthcare Tech

AI Drug Discovery / Computational Biology

Public AI drug discovery platform (NASDAQ: RXRX). 5 clinical programs. Merged with Exscientia ($688M). 2025 rev $74.7M. $755M cash. Founded 2013, Salt Lake City.

AI VisibilityBeta
Overall Score
C56
Category Rank
#167 of 596
AI Consensus
72%
Trend
stable
Per Platform
ChatGPT
56
Perplexity
60
Gemini
53

About

Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B.

Full profile
Cardinal Health logo

Cardinal Health

LeaderHealthcare Tech

Enterprise

Dublin OH pharmaceutical distribution (NYSE: CAH) $230B+ revenue; specialty pharma GLP-1 distribution tailwind, at-Home Solutions growth, medical divestiture to Medline competing with McKesson and Cencora.

AI VisibilityBeta
Overall Score
B79
Category Rank
#20 of 596
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
75
Gemini
77

About

Cardinal Health, Inc. is a Dublin, Ohio-based healthcare distribution and medical products company — publicly traded on the New York Stock Exchange (NYSE: CAH) as an S&P 500 Health Care component — distributing pharmaceutical products to pharmacies, hospitals, and healthcare providers, and manufacturing and distributing medical and surgical supplies through approximately 44,000 employees. In fiscal year 2025 (ending June 2025), Cardinal Health generated revenues exceeding $230 billion in its Pharmaceutical and Specialty Solutions segment — reflecting the company's role as a pass-through distributor of branded and generic pharmaceuticals at near-zero margin on drug cost, where Cardinal Health earns distribution fees and rebate income on enormous volumes. CEO Jason Hollar has executed a two-segment strategy focused on optimizing pharmaceutical distribution (Pharmaceutical and Specialty Solutions — $227B+ revenue at low margin) and growing medical products profitability (Global Medical Products and Distribution — higher-margin branded surgical products, Cardinal Health brand commodities, and at-Home Solutions). The 2024 divestiture of the medical segment's Cardinal Health Brand product line to Medline Industries for $1.1 billion simplified the medical segment focus toward specialty distribution and home healthcare supply. Cardinal Health's specialty pharmaceutical distribution (oncology, rheumatology, rare disease biologics through Cardinal Health Specialty Solutions) is a growing higher-margin subsegment as pharmaceutical manufacturers contract with specialty distributors for controlled dispensing of limited-distribution drugs.

Full profile

AI Visibility Head-to-Head

56
Overall Score
79
#167
Category Rank
#20
72
AI Consensus
90
stable
Trend
stable
56
ChatGPT
79
60
Perplexity
75
53
Gemini
77
51
Claude
77
62
Grok
79

Key Details

Category
AI Drug Discovery / Computational Biology
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Recursion Pharmaceuticals
AI Drug Discovery / Computational Biology

Integrations

Only Recursion Pharmaceuticals
Only Cardinal Health
Recursion Pharmaceuticals is classified as company. Cardinal Health is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.